PTT 003
Alternative Names: PTT-003Latest Information Update: 07 Mar 2025
At a glance
- Originator Pyrotech Therapeutics
- Class Plasma expanders; Urologics; Vascular disorder therapies
- Mechanism of Action Pyroptosis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atherosclerosis; Chemotherapy-induced damage; CNS disorders; Kidney disorders
Most Recent Events
- 07 Mar 2025 Preclinical trials in Atherosclerosis in China (unspecified route) prior to March 2025 (Pyrotech Therapeutics pipeline, March 2025)
- 07 Mar 2025 Preclinical trials in Chemotherapy-induced damage in China (unspecified route) prior to March 2025 (Pyrotech Therapeutics pipeline, March 2025)
- 07 Mar 2025 Preclinical trials in CNS disorders in China (unspecified route) prior to March 2025 (Pyrotech Therapeutics pipeline, March 2025)